NOAC`s in tripletherapy

New knowledge to low dosed NOAC`s in triple therapy according to european guidelines and the following article: "Comparartive efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies", published from Dr. Morimoto T, et al. in the Journal of Cardiology in July, 7 of 2015 . There are statistical significant fewer major bleedings under Edoxaban 30 mg than under Dabigatran 110 mg while both medicines are statistically equal in efficacy. Under Rivaroxaban 15 mg there are statistically significant fewer strokes and systemic embolism, but statistically more major bleedings than under Edoxaban 30mg. The combined rate for stroke, systemic embolism and major bleeding is higher under Rivaroxaban 15 mg than under Edoxaban 30 mg. You must treat 364 patients with Edoxaban 30 mg in triple therapy over 3 months to prevent one major bleeding compared with dabigatran 110 mg. You must treat 271 patiens with Edoxaban 30 mg in triple therapy over 3 months to prevent one stroke oder one systemic embolism or one major bleeding compared with Rivaroxaban 15 mg.
Source: Doc2Doc BMJ Cardiology - Category: Cardiology Authors: Source Type: forums